To further investigate how the therapeutic sclerostin antibody which targeted both loop2 and loop3, aggravated AA and atherosclerosis in Col1a2+/G610C.ApoE-/- mice with AngII infusion, the above parameters indicating AA and atherosclerosis progression were analyzed after administration of antibody with and without pretreatment of loop2m (6 mg/kg, fatty acid-conjugated, twice per week). The gene discussed is COL1A2; the disease is atherosclerosis.